Vestmark Advisory Solutions Inc. Has $292,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Vestmark Advisory Solutions Inc. lessened its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 55.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,029 shares of the company's stock after selling 8,643 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Moderna were worth $292,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in MRNA. Wilmington Savings Fund Society FSB grew its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC increased its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after buying an additional 388 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MRNA. Berenberg Bank lifted their price objective on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Finally, Citigroup began coverage on shares of Moderna in a research report on Thursday. They set a "neutral" rating and a $40.00 target price for the company. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of "Hold" and a consensus price target of $59.60.

Remove Ads

Moderna Trading Down 2.0 %

Shares of NASDAQ MRNA traded down $0.71 during midday trading on Thursday, reaching $34.30. The company's stock had a trading volume of 9,411,394 shares, compared to its average volume of 12,472,202. The stock has a 50 day simple moving average of $36.25 and a 200-day simple moving average of $48.01. The stock has a market capitalization of $13.23 billion, a price-to-earnings ratio of -3.70 and a beta of 1.86. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.